XOMA Royalty Corporation successfully completed its tender offer to acquire all outstanding shares of Generation Bio Co. for $4.2913 per share in cash plus one contingent value right. Approximately 70% of Generation Bio's outstanding shares were validly tendered by the February 6, 2026 expiration date, satisfying the minimum tender condition. Fol...

Monteverde & Associates PC, a class action securities firm, has launched investigations into four merger transactions: First Foundation Inc.'s sale to FirstSun Capital Bancorp, Confluent Inc.'s acquisition by IBM, Generation Bio Co.'s sale to XOMA Royalty Corporation, and Contango Ore Inc.'s merger with Dolly Varden Silver Corporation. The firm i...

XOMA Royalty Corporation announced an agreement to acquire Generation Bio for $4.2913 per share, with additional contingent value rights for stockholders. The acquisition is expected to close in February 2026 and includes potential milestone and royalty payments.

Generation Bio, a biotechnology company, announced that its president and CEO will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on August 13th, 2024.

Generation Bio (GBIO) delivered earnings and revenue surprises of -211.11% and 34.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?